Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We searched all eligible published studies based on the association between codon 72 of the p53 Arg>Pro polymorphism and risk of OC.
|
24747975 |
2014 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to validate the use of PCR-RFLP techniques for the evaluation of p53 codon 72 and CYP1A1 gene polymorphisms in relation with ovarian cancer in a Romanian population and to evaluate gene-environment interaction in this context.
|
22395499 |
2012 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
|
27179933 |
2016 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We present the apparent BRCA1-related, although mutation negative, breast and ovarian cancer patient who subsequently was confirmed to be TP53 c.817C>T (p.R273C) mutation carrier and discuss the importance of peri-diagnostic oncogenetic TP53 testing in early breast cancer cases.
|
21535297 |
2011 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Oncomorphic TP53 mutations were present in 21.3% of ovarian cancers in the TCGA dataset.
|
25385265 |
2015 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
According to the International Agency for Research on Cancer TP53 mutation database, this type of p53 mutation in colorectal cancer and ovarian cancer is 0.13% (5/3,693) and 0% (0/1,494), respectively.
|
20514505 |
2010 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
40 out of 63 (G2/3) patients with G2/3 OC showed mutant p53 and 23 patients showed a wild-type pattern. p53 status was significantly different between these two groups (LMP/G1 vs. G2/3) (P = 0.015).
|
19609560 |
2010 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The early stages of this disease are asymptomatic and more than 75% of the cases are diagnosed with regional or distant metastases. p53 gene is frequently mutated in some histological subtypes of ovarian carcinomas.
|
20414935 |
2010 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Laser-capture microdissected and polymerase chain reaction-amplified DNA revealed reproducible p53 mutations in eight of 14 fully-analysed p53 signatures and all of the 12 TICs; TICs and their associated ovarian carcinomas shared identical mutations.
|
17117391 |
2007 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Intraperitoneal (i.p.) recurrence of cisplatin-refractory and p53 mutant ovarian cancer is a major clinical problem, despite surgery and chemotherapy. dl1520 (ONYX-015) is an E1B-55 kDa gene-deleted adenovirus engineered selectively to replicate in and destroy cancer cells lacking functional p53.
|
11127580 |
2000 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
An abundance of p53 null mutations in ovarian carcinoma.
|
8700537 |
1996 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recently, this category of ovarian carcinoma has gained increasing attention owing to the recognition of morphological varieties of TP53-mutated high-grade ovarian carcinoma.
|
30636633 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
P5091 shows efficacy in suppressing ovarian cancers harbouring wild-type and mutant p53.
|
29049989 |
2017 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
|
27997533 |
2016 |
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We conclude that the association of GSTM1 null/GSTTl null with survival appears to be mediated through different mechanisms to p53 expression in ovarian cancer and in addition, may be a better predictor of outcome.
|
11328408 |
2001 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This large study provides statistical evidence for a small increase in risk of ovarian cancer associated with common variants in the TP53 region.
|
19276375 |
2009 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro.
|
10741907 |
2000 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
TP53 pathway may play pivotal roles in the development of ovarian cancer and TP53 pathway may be a new target for the treatment of ovarian cancer.
|
29565482 |
2018 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21.
|
8679443 |
1996 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Ovarian cancers with a p53 null mutation are more likely to lack telomerase activity.
|
12496479 |
2003 |
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Resistance to chemotherapy and high heterogeneity in mutations contribute to ovarian cancer's lethality, including many mutations in tumor suppressor p53.
|
31039796 |
2019 |
Malignant neoplasm of ovary
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Clinical adenoviral p53 gene therapy has been shown by us and others to inhibit tumor growth of ovarian cancer with endogenous mutant p53.
|
15153938 |
2004 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Both p53 and Bcl-2 were found to be independent prognostic indicators of survival in ovarian cancer.
|
8616869 |
1996 |
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Influence of p53 status on the HSV-Tk/GCV-induced bystander effect in a panel of human ovarian carcinoma cell lines.
|
16050136 |
2005 |